Journals / art / 2018 / Cilt: 33 - Sayı: 1

A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis

Journal
art
Pages
17–25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall five-, 10- and 20-year survival rates of BPLN patients were 94%, 86%, and 71%, respectively, which were higher than those before 1995 (84%, 72%, and 52%, respectively) and lower than those after 1995 (96%, 89%, and 80%, respectively) (all p<0.05).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to conduct a meta-analysis to clarify the epidemiologic characteristics of biopsy-proven lupus nephritis (BPLN), including those relating to its prevalence and prognosis.
📊
Key Findings & Data:The following search terms were used for original articles published between January 1982 and April 2016: “lupus nephritis” or systemic lupus erythematosus (‘SLE’) or ‘systemic lupus erythematous’ and “pathology” or ‘epidemiology’ or prevalence or incidence.
💡
Conclusion & Impact:Overall five-, 10- and 20-year survival rates of BPLN patients were 94%, 86%, and 71%, respectively, which were higher than those before 1995 (84%, 72%, and 52%, respectively) and lower than those after 1995 (96%, 89%, and 80%, respectively) (all p<0.05).
🔬Design:Lab & Field Experiment
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to conduct a meta-analysis to clarify the epidemiologic characteristics of biopsy-proven lupus nephritis (BPLN), including those relating to its prevalence and prognosis. Patients and methods: A literature search for relevant studies was conducted in the electronic databases of PubMed, Google Scholar, Embase, and Cochrane trial register. The following search terms were used for original articles published between January 1982 and April 2016: “lupus nephritis” or systemic lupus erythematosus (‘SLE’) or ‘systemic lupus erythematous’ and “pathology” or ‘epidemiology’ or prevalence or incidence. Pooled estimates with 95% confidence intervals were calculated. Results: Nineteen studies were included (mean age of SLE patients at renal biopsy: ~30 years). Of total BPLN patients, 85% were females. BPLN developed in 29% of SLE patients, and accounted for 60% of secondary glomerular diseases in renal biopsy databases. BPLN prevalence among SLE patients was higher in Saudi Arabia compared with pooled Europe/USA data (43% vs 26%, p<0.05). Pooled BPLN prevalence among secondary glomerular diseases patients was higher in Asian/Latin American countries than in Europe (63% vs 34%, p<0.05). Overall five-, 10- and 20-year survival rates of BPLN patients were 94%, 86%, and 71%, respectively, which were higher than those before 1995 (84%, 72%, and 52%, respectively) and lower than those after 1995 (96%, 89%, and 80%, respectively) (all p<0.05). Class IV nephritis, present in 40% of BPLN patients, was a risk factor for renal failure that contributed to poor prognosis. Conclusion: Lupus nephritis is a common complication of young female patients with SLE, and the most prevalent etiology of secondary glomerular diseases. Attention should be paid to class IV nephritis due to its high frequency and association with poor prognosis.

🔖

Cite This Article

WANG, H., REN, Y., CHANG, J., GU, L., SUN, L. (2018). A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. art, Cilt: 33 - Sayı: 1, 17–25. https://ajindex.com/articles/159679

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ferraccioli G, Gremese E. Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs. G Ital Nefrol 2012;29:655-60. [Abstract] Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev 2013;9:15-9. Ward MM. Cardiovascular and cerebrovascular morbidity and mortality among women with endstage renal disease attributable to lupus nephritis. Am J Kidney Dis 2000;36:516-25.
  2. Faurschou M, Mellemkjaer L, Starklint H, Kamper AL, Tarp U, Voss A, et al. High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol 2011;38:2400-5.
  3. Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012;41:830-9.
  4. Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum 2006;54:2963-9.
  5. Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res Ther 2011;13:240. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
  6. Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004;66:2382-8.
  7. Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 1999;34:315-23.
  8. Descombes E, Droz D, Drouet L, Grünfeld JP, Lesavre P. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997;76:355-68.
  9. Shen K, Yu Y, Tang Z, Liu Z, Li L. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases. Chin Med J (Engl) 1997;110:502-7.
  10. Esdaile JM, Abrahamowicz M, MacKenzie T, Hayslett JP, Kashgarian M. The time-dependence of longterm prediction in lupus nephritis. Arthritis Rheum 1994;37:359-68.
  11. Rabbani MA, Memon GM, Ahmad B, Memon S, Tahir SA, Tahir S. Percutaneous renal biopsy results: a retrospective analysis of 511 consecutive cases. Saudi J Kidney Dis Transpl 2012;23:614-8. 23. Kurnatowska I, Jedrzejka D, Malyska A, WagrowskaDanilewicz M, Danilewicz M, Nowicki M. Trends in the incidence of biopsy-proven